Sanofi wins EU nod for Zaltrap in colon cancer; Sales hike helps Perrigo top earnings forecast;

@FiercePharma: Exanatide (Bydureon and Byetta), now sold by BMS/AZ, helped obese teens lose some weight in small study. More | Follow @FiercePharma

@EricPFierce: Ranbaxy plant problems devastate its share of generic Lipitor market. Report | Follow @EricPFierce

@AlisonBFierce: The FDA approved Sun Pharma's generic version of Johnson & Johnson's cancer drug Doxil to end a months-long shortage. News | Follow @AlisonBFierce

> Sanofi's ($SNY) Zaltrap drug won European approval to treat advanced colorectal cancer. Report

> Perrigo ($PRGO) beat expectations with a 6% rise in quarterly earnings, as rising sales in consumer healthcare offset rising costs. Report

> South Africa's Aspen Pharmacare is eyeing an active pharmaceutical ingredient plant in the Netherlands owned by Merck's ($MRK) Organon unit; the potential buy includes a portfolio of products. Report

> The United Arab Emirates suspended the Bayer acne and contraceptive pill Diane-35 after French health authorities raised questions about its safety. Report

> Becton Dickinson ($BDX) reported higher profits for the quarter--$625.4 million--thanks to an early flu season. Report

> Drug distributor Cardinal Health ($CAH) posted a 6% rise in quarterly earnings, fueled by increased generic drug sales. Report

Biotech News

 @FierceBiotech: Popular yesterday on : $ALNY licenses away hot PCSK9 prospect in 'small' $205M deal. Article | Follow @FierceBiotech

@JohnCFierce: This is my weird deal of the week: Merck KGaA gets option on MS therapeutic vaccine. Story | Follow @JohnCFierce

@RyanMFierce: Merck Serono risks short money ($5M upfront) in this MS option deal w/ Opexa. Echoes of Celsion's China pact for ThermoDox. | Follow @RyanMFierce

> Merck execs struggle with growing uncertainty over late-stage R&D. Article

> Left on FDA 'hold,' Idenix hangs up on once-hot hep C drugs. Story

Medical Device News

 @FierceMedDev: Popular yesterday: GE, NFL to pour $50M into concussion imaging tech. Story | Follow @FierceMedDev

 @MarkHFierce: Becton Dickinson's 2013 Q1 numbers impress. More | Follow @MarkHFierce

 @DamianFierce: Take a look at our list of last year's 10 most important FDA approvals in medical devices and diagnostics. Special Report | Follow @DamianFierce

> Edwards rides Sapien sales to big Q4. Story

> New needle free blood Dx targets anemia in India. Item

> Israel's NeuroQuest targets summer start for Alzheimer's blood Dx pivotal trial. Report

Biotech Research News

> New Alzheimer's drug clears amyloid tangles in mice. Item

> Gene discovery could provide relief for deadly staph infections. Report

> New target that stops metastasis could lead to safer cancer therapies. News

> Merck Serono, Feinstein Institute form collaboration to find lupus treatments. Story

Pharma Manufacturing News

> Ranbaxy production glitch devastates its generic Lipitor biz. News

> Aspen to buy Merck API plant in Netherlands to feed expansion. Article

> Ben Venue Bedford plant still missing GMP standards. Story

> FDA nails Novo for missing 850 samples over 2 years. Report

And Finally... Severely obese teens lost a modest amount of weight on exanatide, a diabetes drug sold in two formulations by Bristol-Myers Squibb ($BMY) and AstraZeneca ($AZN). Report

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.